I kliniske studier af hypertensive patienter havde Riprazo ingen klinisk signifikant virkning på total kolesterol, HDL- kolesterol, fastende triglycerider, fastende glukose eller urinsyre.
In clinical studies in hypertensive patients, Riprazo had no clinically important effects on total cholesterol, high density lipoprotein cholesterol (HDL-C), fasting triglycerides, fasting glucose or uric acid.